Category - Developments

Developments

Cybin receives conditional listing approval from NYSE American

Cybin (NEO:CYBN; OTCQB:CLXPF) has received conditional listing approval from the NYSE American stock exchange, under the ticker symbol, CYBN. In a statement, Doug Drysdale, CEO of Cybin, said conditional listing...

July 22, 2021

Developments

Cognetivity ICA test to be deployed in new NHS brain clinic in UK

Cognetivity Neurosciences’ (CSE:CGN; OTCQB:CGNSF) Integrated Cognitive Assessment (ICA) test is to form an integral part of a new and highly innovative clinic in the UK’s National Health Service (NHS) dedicated to...

July 15, 2021

Developments

TransMedics receives positive FDA AdCom vote for OCS Liver System

The FDA’s Gastroenterology and Urology Devices Panel, after a review and discussion, issued a favorable vote in support of approval of TransMedics Group’s (NASDAQ:TMDX) OCS Liver System. The panel voted 14-to-0...

July 15, 2021

Developments

ENA Respiratory begins Phase 1 study of COVID-19 preventative nasal spray

Closely-held ENA Respiratory of Australia initiated a Phase 1 human safety study of INNA-051, being developed to activate innate immunity in the nose, the primary entry portal of most respiratory viral infections. ...

July 14, 2021

Developments

Mesosil raises $675,000 seed round led by Archangel and NorthSpring Capital

Mesosil, a closely-held company developing the first lifetime-effect antimicrobial materials for dental and medical devices, closed an initial seed round of $675,000 led by the Archangel Network of Funds and NorthSpring...

July 13, 2021

Developments

Hepion posts positive Phase 2a NASH data in AMBITION trial

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that all primary endpoints were met in its Phase 2a AMBITION clinical trial in patients with non-alcoholic steatohepatitis (NASH). The Phase 2a trial was designed to...

July 13, 2021

Developments

FDA approves expanded use for Pivot smoking cessation sensor

Carrot Inc., a closely-held digital health company, received expanded use indications for its Pivot Carbon Monoxide Breath Sensor in a new 510(k) clearance by the FDA based on published clinical trial data. As the only...

July 12, 2021

Developments

Lumos Diagnostics raises $63-million (Australian) in IPO

Lumos Diagnostics, with corporate head offices in Melbourne and U.S.-based R&D, commercial operations and manufacturing in both Florida and California, raised $63-million (Australian) in an initial public...

July 8, 2021

Developments

Advaxis and Biosight in merger pact

Advaxis (NASDAQ:ADXS) and closely-held Biosight of Israel entered into a definitive merger agreement, with shareholders of Biosight becoming the majority holders of the combined company. Advaxis will be renamed Biosight...

July 7, 2021

Developments

Seelos doses first patient in Part 2 of registration trial with intranasal racemic ketamine

Seelos Therapeutics (NASDAQ:SEEL) dosed the first patient in Part 2 of its registrational proof-of-concept study of SLS-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior in patients with major...

July 6, 2021

Category - Developments

Cybin receives conditional listing approval from NYSE American

Cognetivity ICA test to be deployed in new NHS brain clinic in UK

TransMedics receives positive FDA AdCom vote for OCS Liver System

ENA Respiratory begins Phase 1 study of COVID-19 preventative nasal spray

Mesosil raises $675,000 seed round led by Archangel and NorthSpring Capital

Hepion posts positive Phase 2a NASH data in AMBITION trial

FDA approves expanded use for Pivot smoking cessation sensor

Lumos Diagnostics raises $63-million (Australian) in IPO

Advaxis and Biosight in merger pact

Seelos doses first patient in Part 2 of registration trial with intranasal racemic ketamine

General

More